NewAmsterdam Pharma Company N.V. Ordinary Shares - Asset Resilience Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has an Asset Resilience Ratio of 20.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Asset Resilience Ratio has changed over time. Check NAMS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down NewAmsterdam Pharma Company N.V. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of NewAmsterdam Pharma Company N.V. Ordinar.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $164.54 Million | 20.92% |
| Total Liquid Assets | $164.54 Million | 20.92% |
Asset Resilience Insights
- Good Liquidity Position: NewAmsterdam Pharma Company N.V. Ordinary Shares maintains a healthy 20.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
NewAmsterdam Pharma Company N.V. Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare NewAmsterdam Pharma Company N.V. Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares (2023–2024)
The table below shows the annual Asset Resilience Ratio data for NewAmsterdam Pharma Company N.V. Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.22% | $62.45 Million | $864.62 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $347.10 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more